Merck & Co., Inc. (MRK) stock
MRKNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 4, 2026Score 9/30240% above fair value
$143.37−1.09 (-0.75%)
Close on Nov 17, 2026Market cap $353.72BP/E 114.7Yield 2.29%
Merck revenue
Revenue is the money a company takes in from selling its products and services, before any costs are deducted.
Merck's revenue for the twelve months ending Jun 30, 2026 was $66.57B, up 4.6% year over year. For fiscal 2025 it was $65.01B, up 1.3% from the year before. Over ten years it grew 5.1% a year on average. The highest annual figure on record is $65.01B in fiscal 2025.
Annual revenue
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $65.01B | +1.3% |
| FY2024 | Dec 31, 2024 | $64.17B | +6.7% |
| FY2023 | Dec 31, 2023 | $60.12B | +1.4% |
| FY2022 | Dec 31, 2022 | $59.28B | +21.7% |
| FY2021 | Dec 31, 2021 | $48.70B | +17.3% |
| FY2020 | Dec 31, 2020 | $41.52B | +6.1% |
| FY2019 | Dec 31, 2019 | $39.12B | -7.5% |
| FY2018 | Dec 31, 2018 | $42.29B | +5.4% |
| FY2017 | Dec 31, 2017 | $40.12B | +0.8% |
| FY2016 | Dec 31, 2016 | $39.81B | +0.8% |
| FY2015 | Dec 31, 2015 | $39.50B | -6.5% |
| FY2014 | Dec 31, 2014 | $42.24B | -4.1% |
| FY2013 | Dec 31, 2013 | $44.03B | -6.8% |
| FY2012 | Dec 31, 2012 | $47.27B | -1.6% |
| FY2011 | Dec 31, 2011 | $48.05B | +4.5% |
| FY2010 | Dec 31, 2010 | $45.99B | +67.7% |
| FY2009 | Dec 31, 2009 | $27.43B | +15.0% |
| FY2008 | Dec 31, 2008 | $23.85B | -1.4% |
| FY2007 | Dec 31, 2007 | $24.20B | – |
Quarterly revenue
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | $16.61B | +5.1% |
| Q1 FY2026 | Mar 31, 2026 | $16.29B | +4.9% |
| Q4 FY2025 | Dec 31, 2025 | $16.40B | +5.0% |
| Q3 FY2025 | Sep 30, 2025 | $17.28B | +3.7% |
| Q2 FY2025 | Jun 30, 2025 | $15.81B | -1.9% |
| Q1 FY2025 | Mar 31, 2025 | $15.53B | -1.6% |
| Q4 FY2024 | Dec 31, 2024 | $15.62B | +6.8% |
| Q3 FY2024 | Sep 30, 2024 | $16.66B | +4.4% |
| Q2 FY2024 | Jun 30, 2024 | $16.11B | +7.2% |
| Q1 FY2024 | Mar 31, 2024 | $15.78B | +8.9% |
| Q4 FY2023 | Dec 31, 2023 | $14.63B | +5.8% |
| Q3 FY2023 | Sep 30, 2023 | $15.96B | +6.7% |
| Q2 FY2023 | Jun 30, 2023 | $15.04B | +3.0% |
| Q1 FY2023 | Mar 31, 2023 | $14.49B | -8.9% |
| Q4 FY2022 | Dec 31, 2022 | $13.83B | +2.3% |
| Q3 FY2022 | Sep 30, 2022 | $14.96B | +13.7% |
| Q2 FY2022 | Jun 30, 2022 | $14.59B | +28.0% |
| Q1 FY2022 | Mar 31, 2022 | $15.90B | +49.6% |
| Q4 FY2021 | Dec 31, 2021 | $13.52B | +23.5% |
| Q3 FY2021 | Sep 30, 2021 | $13.15B | +20.4% |
| Q2 FY2021 | Jun 30, 2021 | $11.40B | +21.9% |
| Q1 FY2021 | Mar 31, 2021 | $10.63B | -11.9% |
| Q4 FY2020 | Dec 31, 2020 | $10.95B | +163.9% |
| Q3 FY2020 | Sep 30, 2020 | $10.93B | -11.8% |
| Q2 FY2020 | Jun 30, 2020 | $9.35B | -20.5% |
| Q1 FY2020 | Mar 31, 2020 | $12.06B | +11.5% |
| Q4 FY2019 | Dec 31, 2019 | $4.15B | -62.3% |
| Q3 FY2019 | Sep 30, 2019 | $12.40B | +14.9% |
| Q2 FY2019 | Jun 30, 2019 | $11.76B | +12.4% |
| Q1 FY2019 | Mar 31, 2019 | $10.82B | +7.8% |
| Q4 FY2018 | Dec 31, 2018 | $11.00B | +5.4% |
| Q3 FY2018 | Sep 30, 2018 | $10.79B | +4.5% |
| Q2 FY2018 | Jun 30, 2018 | $10.47B | +5.4% |
| Q1 FY2018 | Mar 31, 2018 | $10.04B | +6.4% |
| Q4 FY2017 | Dec 31, 2017 | $10.43B | +3.1% |
| Q3 FY2017 | Sep 30, 2017 | $10.33B | -2.0% |
| Q2 FY2017 | Jun 30, 2017 | $9.93B | – |
| Q1 FY2017 | Mar 31, 2017 | $9.43B | – |
| Q4 FY2016 | Dec 31, 2016 | $10.12B | – |
| Q3 FY2016 | Sep 30, 2016 | $10.54B | – |
See a number that looks wrong?